Literature DB >> 7858484

Hepatic growth induced by injection of the liver growth factor into normal rats.

J J Díaz Gil1, C Rúa, C Machin, R M Cereceda, R García-Cañero, M de Foronda, J Pérez de Diego, C Trilla, P Escartin.   

Abstract

Normal Wistar rats injected with the liver growth factor (LGF), a mitogen specific for liver cells, experienced hepatic growth. LGF shows two peaks of activity in vivo, both of them mitogenic. Rats injected either with 6.8 ng or 3.9 micrograms LGF/rat every 3-4 days experienced liver growth showing a see-saw profile. Dry liver weight usually peaked at day 2 (microgram doses) or at day 3 (ng doses) after each injection, with increases of about 30% over controls. Liver DNA synthesis, measured by [3H]-thymidine incorporation, peaked 24 h after LGF injection at both doses. Liver protein synthesis, measured by [14]C-leucine incorporation, usually peaked 24 h after DNA synthesis maximums. Mitogen-stimulated cells were also assessed by immunohistochemical staining for proliferating cell nuclear antigen in livers of LGF-injected rats. Rats injected with rat serum albumin purified from normal rats to serve as controls showed a 6% increase in dry liver weight, but when serum albumin from 3-day fasted rats was injected instead, the increase was not statistically significant. The mild effect of rat serum albumin could be due to the lipid content of the solutions injected, but the level of lipids/mg protein in LGF solutions was half that determined with serum albumin from 3-day fasted rats. From the microscopic and ultramicroscopic studies carried out in rat livers injected with LGF at each dose, we observed: (1) an increase in the number of hepatocytes undergoing mitosis; (2) transient increases in lipid and glycogen contents, as occur after liver resection; (3) no signs of degeneration, such as the appearance of amyloids or fibrosis; (4) no increase in lysosome number, as in hepatotoxicity; (5) no alterations in endothelial or Kupffer cells; and (6) no ultrastructural signs of degeneration either in cytoplasmic organelles (rough endoplasmic reticulum, mitochondria) or in nuclei. One year after LGF injection, rat liver, pancreas, kidneys and spleen were normal, with no signs of degeneration or onset of fibrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858484

Source DB:  PubMed          Journal:  Growth Regul        ISSN: 0956-523X


  10 in total

1.  Mobilization of neural stem cells and generation of new neurons in 6-OHDA-lesioned rats by intracerebroventricular infusion of liver growth factor.

Authors:  Rafael Gonzalo-Gobernado; Diana Reimers; Antonio S Herranz; Juan José Díaz-Gil; Cristina Osuna; María José Asensio; Silvia Baena; Macarena Rodríguez-Serrano; Eulalia Bazán
Journal:  J Histochem Cytochem       Date:  2009-02-02       Impact factor: 2.479

Review 2.  Role of Liver Growth Factor (LGF) in Parkinson's Disease: Molecular Insights and Therapeutic Opportunities.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  Mol Neurobiol       Date:  2021-02-19       Impact factor: 5.590

3.  Effect of liver growth factor on both testicular regeneration and recovery of spermatogenesis in busulfan-treated mice.

Authors:  Miriam Pérez-Crespo; Eva Pericuesta; Serafín Pérez-Cerezales; Maria I Arenas; Maria V T Lobo; Juan J Díaz-Gil; Alfonso Gutierrez-Adan
Journal:  Reprod Biol Endocrinol       Date:  2011-02-04       Impact factor: 5.211

Review 4.  Liver growth factor as a tissue regenerating factor in neurodegenerative diseases.

Authors:  Rafael Gonzalo-Gobernado; Lucia Calatrava-Ferreras; Juan Perucho; Diana Reimers; MarIa J Casarejos; Antonio S Herranz; Adriano Jimenez-Escrig; Juan J Diaz-Gil; Eulalia Bazan
Journal:  Recent Pat CNS Drug Discov       Date:  2014

5.  Neuroprotective role of liver growth factor "LGF" in an experimental model of cerebellar ataxia.

Authors:  Lucía Calatrava-Ferreras; Rafael Gonzalo-Gobernado; Diana Reimers; Antonio S Herranz; Adriano Jiménez-Escrig; Juan José Díaz-Gil; María José Casarejos; María Teresa Montero-Vega; Eulalia Bazán
Journal:  Int J Mol Sci       Date:  2014-10-21       Impact factor: 5.923

6.  Proliferative activity of liver growth factor is associated with an improvement of cigarette smoke-induced emphysema in mice.

Authors:  Álvaro Girón-Martínez; Sandra Pérez-Rial; Raúl Terrón-Expósito; Juan José Díaz-Gil; Nicolás González-Mangado; Germán Peces-Barba
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

7.  Liver Growth Factor Induces Glia-Associated Neuroprotection in an In Vitro Model of Parkinson´s Disease.

Authors:  Rafael Gonzalo-Gobernado; Diana Reimers; María José Casarejos; Lucía Calatrava Ferreras; Manuela Vallejo-Muñoz; Adriano Jiménez-Escrig; Juan José Diaz-Gil; Gonzalo M Ulzurrun de Asanza; Eulalia Bazán
Journal:  Brain Sci       Date:  2020-05-22

8.  Liver Growth Factor "LGF" as a Therapeutic Agent for Alzheimer's Disease.

Authors:  Rafael Gonzalo-Gobernado; Juan Perucho; Manuela Vallejo-Muñoz; Maria José Casarejos; Diana Reimers; Adriano Jiménez-Escrig; Ana Gómez; Gonzalo M Ulzurrun de Asanza; Eulalia Bazán
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

9.  Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's disease.

Authors:  Rafael Gonzalo-Gobernado; Lucía Calatrava-Ferreras; Diana Reimers; Antonio Sánchez Herranz; Macarena Rodríguez-Serrano; Cristina Miranda; Adriano Jiménez-Escrig; Juan José Díaz-Gil; Eulalia Bazán
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

10.  Liver Growth Factor (LGF) Upregulates Frataxin Protein Expression and Reduces Oxidative Stress in Friedreich's Ataxia Transgenic Mice.

Authors:  Lucía Calatrava-Ferreras; Rafael Gonzalo-Gobernado; Diana Reimers; Antonio S Herranz; María J Casarejos; Adriano Jiménez-Escrig; Javier Regadera; Juan Velasco-Martín; Manuela Vallejo-Muñoz; Juan José Díaz-Gil; Eulalia Bazán
Journal:  Int J Mol Sci       Date:  2016-12-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.